Solution structure of a unique C5a semi-synthetic antagonist: Implications in receptor binding

Protein Science

Volumn 6, Issue 1, 1997, Pages 65-72

  Zhang, Xiaolu ^a   Boyar, William ^a   Galakatos, Nicholas ^b   Gonnella, Nina C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Venrock Associates   (United States)

Author keywords

NMR; protein structure; receptor antagonist; recombinant human C5a

Indexed keywords

COMPLEMENT COMPONENT C5A;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; DNA TEMPLATE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; RECEPTOR BINDING; TARGET CELL; X RAY CRYSTALLOGRAPHY;

EID: 0031021601     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560060107     Document Type: Article

References (45)

1. Aue WP, Bartholdi E, Ernst RR. 1976. Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J Chem Phys 64:2229-2246.
2. 1H nuclear magnetic resonance spectra. J Mol Biol 155:321-346.
3. Boulay F, Mery L, Tardif M, Brouchon L, Vignais P. 1991. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30:2993-2999.
4. Braunschweiler L, Bodenhausen G, Ernst RR. 1983. Analysis of networks of coupled spins by multiple quantum N.M.R. Mol Phys 48:535-560.
5. 125I]C5a to human neutrophil, monocyte and U-937 cell membranes. Mol Immunol 29:1319-1324.
6. Brünger AT. 1993. X-PLOR version 3.1. A system for X-ray crystallography and NMR. New Haven, Connecticut: Yale University Press.
7. 1H NMR parameters of the common amino acid residues measured in aqueous solutions of the linear tetrapeptides H-Gly-Gly-X-L-Ala-OH. Biopolymers 18:285-297.
8. Carney DF, Hugh TE. 1993. Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor. Protein Sci 2:1391-1399.
9. Chenoweth DE, Hugli TE. 1978. Demonstration of a specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 75:3943-3947.
10. Chenoweth DE, Hugli TE. 1980. Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol 17:151-161.
11. Craddock PR, Hammerschmidt D, White JG, Dalmasso AP, Jacob HS. 1977. Complement (C5a)-induced granulocyte aggregation in vitro. J Clin Invest 60:260-264.
12. Crawford MH, Grover EL, Kolb WP, McMahan CA, O'Rourde RA, McManus LM, Pinckarrd RW. 1988. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78:1449-1458.
13. 1H NMR spectra via two-dimensional homonuclear Hartmann-Hahn spectroscopy. J Am Chem Soc 107:2820-2821.
14. Eich G, Bodenhausen G, Ernst RR. 1982. Exploring nuclear spin systems by relayed magnetization transfer. J Am Chem Soc 104:3731-3732.
15. Fernandez HN, Henson PM, Otani A, Hugli TE. 1978. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J Immunol 120:109-115.
16. Gerard C, Gerard NP. 1994. C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 12:775-808.
17. Gerard NP, Gerard C. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature (Lond) 349:614-617.
18. Hugli T. 1981. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a and C5a. Crit Rev Immunol 1:321-366.
19. Jeener J, Meier BH, Bachmann P, Ernst RR. 1979. Investigation of exchange processes by two-dimensional NMR spectroscopy. J Chem Phys 71:4546-4553.
20. Johnson RJ, Tamerius JD, Chenoweth DE. 1987. Identification of an antigenic epitope and receptor binding domain of human C5a. J Immunol 138:3856-3862.
21. Lanza T, Durette PL, Rollins T, Siciliano S, Cianciarulo DN, Kobayashi SV, Caldwell CG, Springer MS, Hagmann WK. 1992. Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding. J Med Chem 35:252-258.
22. 1H spin-spin coupling constants in proteins. Biochem Biophvs Res Commun 113:967-974.
23. Miller JJ III, Olds LC, Huene DB. 1986. Complement activation products and factors influencing phagocytic migration in synovial fluids from children with chronic arthritis. Clin Exp Rheumatol 3:53-56.
24. Mollison KW, Fey TA, Krause RA, Miller L, Edalji RP, Conway RG, Mandecki W, Shallcross MA, Kawai M, Or YS, Lane B, Carter GW. 1991. C5a structural requirements for neutrophil receptor interaction. Prog Inflammation Res Ther Int Conf Inflammation Res Assoc 5th 35:17-21.
25. Mollison KW, Mandecki W, Zuiderweg EPR, Fayer L, Fey TA, Krause RA, Conway RG, Miller L, Edalji RP, Shallcross MA, Lane B, Fox JL, Greer J, Carter GW. 1989. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci USA 86:292-296.
26. Morgan E, Ember JA, Sanderson SD, Schloz W, Buchner R, Ye RD, Hugli TE. 1993. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol 151:377-388.
27. 2 ridges in 2D NMR spectra and procedures for suppression. J Magn Reson 66:187-193.
28. Ozaki T, Hayashi H, Tani K, Ogushi F, Yasuoka S, Ogura T. 1992. Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 145:85-91.
29. 1H NMR spectra of proteins using multiple-quantum coherence. J Magn Reson 66:372-378.
30. Robbins RA, Russ RD, Rasmussen KK, Clayton MM. 1987. Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis 135:651-658.
31. Schroder JM, Gregory H, Young Y, Christophers E. 1992. Neutrophil-activating proteins in psoriasis. J Invest Dermatol 98:241-247.
32. Seligmann B, Patel K, Haston W, Rediske JJ. 1987. Fluorometer based multiparameter analysis of phagocytic cell activation. Agents and Actions 21:375-378.
33. Serhan CN, Radin A, Smolen JE, Korchal H, Samuelsson B, Weissmann G. 1982. Leukotriene B4 is a complete secretagogue in human neutrophils: A kinetic analysis. Biochem Biophys Res Commun 107:1006-1012.
34. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Ripper G, Bondy S, Rosen H, Springer MS. 1994. Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 91:1214-1218.
35. Swerlick RA, Yancey KB, Lawley TJ. 1988. A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol 140:2376-2381.
36. Toth MJ, Huwyler L, Boyar WC, Braunwalder AF, Yarwood D, Hadala J, Haston WO, Sills MA, Seligmann B, Galakatos N. 1994. The pharmacophore of the human C5a anaphylatoxin. Protein Sci 3:1159-1168.
37. Weisman HF, Barton T, Leppo MK, Marcsh HC Jr, Carson GR, Concino MF, Boyle MP, Raux KH, Weisfeldt MC, Fearon DT. 1990. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-151.
38. Wetsel RA. 1995. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 7:48-53.
39. 1H nuclear magnetic resonance data. Biochemistry 29:2895-2905.
40. Wüthrich K. 1986. NMR of proteins and nucleic acids. New York: John Wiley & Sons.
41. Yoshizawa Y, Nomura A, Ohdama S, Ranaka M, Morinari H, Hasegawa S. 1988. The significance of complement activation in the pathogenesis of hypersensitivity pneumonitis: Sequential changes of complement components and chemotactic activities in bronchoalveolar lavage fluids. Int Arch Allergy Appl Immunol 87:417-423.
42. Zarbock J, Gennaro R, Romeo D, Clore GM, Gronenbom AM. 1988. A proton nuclear magnetic resonance study of the conformation of bovine anaphylatoxin C5a in solution. FEBS Lett 238:289-294.
43. ω-C5a, from porcine serum. Hoppe Seyler's Z Physiol Chem 365:151-158.
44. 1H-NMR methyl lines and conformation of valyl residues in the lac represser headpiece. Biopolvmers 24:601-611.
45. Zuiderweg ERP, Nettesheim DG, Mollison KW, Carter GW. 1989. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 28:172-185.